You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
"今年最賺錢新股"沛嘉醫療-B午後飆升,創上市新高
uSMART友信智投 05-20 14:48

uSMART友信智投5月20日消息,週三港股,上市第四天的次新股沛嘉醫療-B繼續發力,午後漲幅進一步擴大,截至北京時間13時37分,沛嘉醫療-B漲7.1%,報28.65港元,最高觸及28.8港元,股價創上市以來新高,若打新中簽持有至今,不計手續費,一手最高賺13,440港元。

沛嘉醫療-B引爆近期新股市場,公開認購過千倍、國際配售20倍,機構、散戶齊齊搶破頭,可謂"一簽難求"。最終,沛嘉醫療-B也一舉超越康方生物晉升為新的凍資王和十年最賺錢新股,其首日最高漲幅達到77%,一手大賺1萬元。

沛嘉醫療于2012年成立,專注於經導管瓣膜治療醫療器械市場,以及神經介入手術醫療器械市場。其中,用於治療主動脈瓣疾病的TaurusOne已完成臨床試驗,預計于第3季提交註冊申請。

高瓴持股沛嘉醫療近10%

沛嘉醫療-B的喜人成績,讓股東高瓴資本再度成為市場投資者的關注焦點。高瓴資本近兩個季度的表現堪稱"神操作",不僅一級市場投得好,二級市場也成績優秀,516日,高瓴資本在美國證券交易委員會(SEC)公佈2020年第一季度末的美股持倉情況,一季度新建倉9只美股,精准抄底特斯拉,第一大重倉股ZOOM,年初至今(截至5月18日收盤)漲幅高達142.05%,詳情閱讀:《怎麼買美股?這裡有一份高瓴資本的作業》

配售結果 | 沛嘉醫療一手中簽率8.5%,公開認購1,184.41倍,國配超購20倍,有綠鞋

暗盤前瞻丨沛嘉醫療、建業新生活:高瓴資本同時入股,國配均獲高雙位數認購

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account